Allakos (NASDAQ:ALLK) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Allakos (NASDAQ:ALLK) from a buy rating to a hold rating in a research note released on Friday morning, Zacks.com reports.

According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States. “

Separately, William Blair reaffirmed a buy rating on shares of Allakos in a research note on Friday, August 9th.



Shares of ALLK stock opened at $89.12 on Friday. The stock has a 50-day simple moving average of $50.60 and a 200 day simple moving average of $42.71. Allakos has a fifty-two week low of $29.34 and a fifty-two week high of $92.84.

Allakos (NASDAQ:ALLK) last announced its earnings results on Monday, August 5th. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. As a group, sell-side analysts predict that Allakos will post -1.83 EPS for the current fiscal year.

In other news, Director John P. Mckearn sold 53,906 shares of Allakos stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $39.57, for a total transaction of $2,133,060.42. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John P. Mckearn sold 38,732 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $39.80, for a total value of $1,541,533.60. The disclosure for this sale can be found here. Insiders have sold a total of 186,373 shares of company stock worth $7,408,059 in the last three months. 52.11% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of ALLK. Bank of New York Mellon Corp raised its stake in shares of Allakos by 53.6% in the 4th quarter. Bank of New York Mellon Corp now owns 33,403 shares of the company’s stock valued at $1,746,000 after acquiring an additional 11,660 shares in the last quarter. Northern Trust Corp raised its stake in shares of Allakos by 3.7% in the 4th quarter. Northern Trust Corp now owns 112,903 shares of the company’s stock valued at $5,902,000 after acquiring an additional 3,994 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Allakos by 264.0% in the 4th quarter. Bank of America Corp DE now owns 4,153 shares of the company’s stock valued at $217,000 after acquiring an additional 3,012 shares in the last quarter. Norges Bank bought a new position in shares of Allakos in the 4th quarter valued at approximately $1,045,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Allakos by 4,853.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,220 shares of the company’s stock valued at $130,000 after acquiring an additional 3,155 shares in the last quarter. Institutional investors and hedge funds own 53.48% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Featured Story: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.